Tumorigenesis has long been thought to be a multistep process (Foulds, 1958); however,
only recently has it become possible to identify the molecular events that underlie the …

Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are
common in diverse types of human cancer. The p53 mutational spectrum differs among …

Engineered nanoparticles have been used to provide diagnostic,,, therapeutic, and
prognostic information, about the status of disease. Nanoparticles developed for these …

Familial cancer syndromes have helped to define the role of tumor suppressor genes in the
development of cancer. The dominantly inherited Li-Fraumeni syndrome (LFS) is of …

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive
functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies …

The cell cycle is composed of a series of steps which can be negatively or postively
regulated by various factors. Chief among the negative regulators is the p53 protein …

Immunohistochemical staining for p53 is used as a surrogate for mutational analysis in the
diagnostic workup of carcinomas of multiple sites including ovarian cancers. Strong and …

Antibody-based targeted immunotherapy has shown promise as an approach to treat
cancer. However, many known tumor-associated antigens are not expressed as integral …

HUMAN hepatocellular carcinomas (HCC) from patients in Qidong, an area of high
incidence in China, in which both hepatitis B virus and aflatoxin B1 are risk factors1, were …

Mutations of the p53 gene occur commonly in colorectal carcinomas and the wild-type p53
allele is often concomitantly deleted. These findings suggest that the wild-type gene may act …